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Abstract
Background—In 2004 the Clinical Consult Case Review (CCCR) working group was formed 
within the CDC-funded Clinical immunization Safety Assessment (CISA) Network to review 
individual cases of adverse events following immunizations (AEFI).
Methods—Cases were referred by practitioners, health departments, or CDC employees. Vaccine 
Adverse Event Reporting System (VAERS) searches and literature reviews for similar cases were 
performed prior to review. After CCCR discussion, AEFI were assessed for a causal relationship 
with vaccination and recommendations regarding future immunizations were relayed back to the 
referring physicians. In 2010, surveys were sent to referring physicians to determine the utility and 
effectiveness of the CCCR service.
Results—CISA investigators reviewed 76 cases during 68 conference calls between April 2004 
and December 2009. Almost half of cases (35/76) were neurological in nature. Similar AEFI for 
the specific vaccines received were discovered for 63 cases through VAERS searches and for 38 
cases through PubMed searches. Causality assessment using the modified WHO criteria resulted 
in classifying 3 cases as definitely related to vaccine administration, 12 as probably related, 16 as 
possibly related, 18 as unlikely related, 10 as unrelated, and 17 had insufficient information to 
assign causality. The physician satisfaction survey was returned by 30 (57.7%) of those surveyed 
and a majority of respondents (93.3%) felt that the CCCR service was useful.
Disclaimer: The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position 
or views of the Centers for Disease Control and Prevention.
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Conclusions—The CCCR provides advice about AEFI to practitioners, assigns potential 
causality, and contributes to an improved understanding of adverse health events following 
immunizations.
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Introduction
Vaccines are one of the greatest public health achievements in the history of medicine. 
Throughout the past century, vaccines have helped to greatly reduce the disease burden from 
both bacterial and viral infections [1-8]. However, as with any medication, vaccines are not 
without risk. Several well documented adverse events have been associated with specific 
vaccines [1, 9-14]. Thus, it is the responsibility of the public health community to 
continuously evaluate potential adverse events following immunization (AEFI), to 
repeatedly assess the risk-benefit profile of each vaccine, and to inform the public if 
additional risks are identified [15-21].
In 2001, the Centers for Disease Control and Prevention established the Clinical 
Immunization Safety Assessment (CISA) Network, a national consortium of six academic 
medical centers with expertise in immunization safety [22]. CISA goals were: (1) to study 
the pathophysiologic basis of adverse events following immunization; (2) to study individual 
risk factors associated with developing an adverse event following immunization; (3) to 
serve as a vaccine safety resource for consultation on complex clinical vaccine safety issues; 
and (4) to assist domestic and global vaccine policy makers in developing guidance for 
individuals who may be at increased risk for AEFIs [23].
To address the third objective, the CISA Clinical Consult Case Review (CCCR) working 
group was established in 2004. The working group meets monthly to address specific 
questions from practitioners regarding individual clinical cases of potential AEFI after 
administration of a licensed vaccine. The CCCR working group consists of investigators and 
research coordinators from each CISA network site, CDC representatives, and subspecialists 
who convene to discuss specific case(s) via regularly scheduled telephone conferences. The 
primary goals of the CCCR are twofold: (1) to provide guidance to medical providers 
regarding subsequent vaccinations, and (2) to provide expert opinion as to the probability 
that the event could have been causally related to vaccination using modified World Health 
Organization (WHO) causality guidelines [18, 24]. (Table 1) The objective of this overview 
is to describe the scope of the cases reviewed, the process of causality determination, and to 
explore the usefulness of this service for health care providers.
Methods
Case Evaluation and Presentation
The CISA network includes investigators from the medical centers of Boston University, 
Columbia University, Johns Hopkins University, Northern California Kaiser Permanente 
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Vaccine Study Center, Stanford University and Vanderbilt University. In addition, board 
certified allergists and neurologists frequently participated in the teleconferences.
Cases were referred to CISA network sites by local providers who were aware of the CCCR 
service, state health departments or the CDC. Additionally, cases were also collected by 
CISA investigators during their clinical responsibilities and presented to the CCCR. Each 
CISA site was responsible for selecting individual cases to present to the group and to 
collect additional clinical data when indicated. These cases were then presented by the CISA 
site on a scheduled teleconference. When available, the provider seeking the consultation 
presented the case to the CCCR and/or actively participated in the discussion. Separate 
CISA working groups for Guillain-Barré syndrome and hypersensitivity existed and 
reviewed those specific adverse events separately. Standardized templates, developed in 
January of 2006, were completed for each case, including a brief description of the case and 
the results of both Vaccine Adverse Event Reporting System (VAERS) database and 
PubMed medical literature searches. VAERS is the national adverse event reporting system 
available to the public to monitor vaccine safety [25]. Reports to VAERS may indicate 
instances of temporal association of the vaccine and AEFI, but are not evidence of causality 
[25]. For each referred clinical case, we conducted VAERS searches including the specific 
vaccine(s), individually or in combination if applicable, linked with the diagnosis or main 
symptoms of the adverse event. Medical literature searches via PubMed were conducted for 
the diagnosis or primary symptom associated with the specific vaccine(s). All documents 
were available on a secure website for participants to review prior to each call.
The CCCR group reviewed the assembled documents and attempted to reach consensus 
regarding causality and recommendations for further immunizations. For some cases, the 
group determined that additional expert opinion or more patient information was needed; 
these cases were discussed again after this information was obtained.
Causality Assessment
WHO causality guidelines were published in 2000 [18] (Table 1), but these were previously 
modified by CISA investigators to more appropriately address AEFI by including supporting 
evidence of a causal association and expanding the criteria regarding biological plausibility 
and likelihood of other known causes for the event. The original and modified WHO 
causality criteria are presented in Table 1 [18, 24].
Recommendations
The recommendations of the working group were summarized in written correspondence to 
the consulting party. Causality assessment and the recommendations regarding future 
vaccinations were included.
Follow-up Survey
During the summer of 2010, each site sent standardized letters and a brief survey to the 
providers who had consulted the CCCR to obtain feedback regarding outcomes of the 
patients discussed, to assess whether the recommendations for future immunizations were 
followed, and to determine whether the review and recommendations by the CCCR were 
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helpful. Three weeks were allowed to receive responses by mail, phone or electronic mail. If 
no response was received, two more attempts were made to contact parties by telephone.
Illustrative cases
Case 1
A 10 month old female infant developed status epilepticus 18 hours after concomitantly 
receiving her third dose of the combination diphtheria and tetanus toxoid, acellular pertussis 
(DTaP), recombinant hepatitis B (Hep B), and inactivated poliovirus (IPV) vaccine, and a 
separate injection of seven-valent pneumococcal conjugate vaccine. She was previously 
healthy with the exception of a one week history of mild cough and rhinorrhea prior to 
vaccination. Her family history was positive in that her father had childhood febrile seizures. 
At the vaccination visit she had a normal physical exam, was afebrile and playful. 
Approximately 18 hours later she developed generalized tonic-clonic seizures. She was 
taken to the emergency department by ambulance where she was found to be febrile to 101.3 
F and continued to have seizures, resulting in intubation and admission to the pediatric 
intensive care unit (PICU). Upon PICU admission, the child was hypertonic and 
hyperreflexic with no focal findings. Otherwise the physical exam was normal. She was 
treated with anticonvulsants, acyclovir, and ceftriaxone and stabilized rapidly.
Laboratory evaluation included a normal complete blood count, metabolic panel, and 
cerebrospinal fluid (CSF) analysis. Blood, urine and CSF bacterial cultures were negative. 
She had a normal head MRI and CT scan, negative pertussis direct fluorescent antibody and 
culture, and negative fluorescent antibody test for adenovirus, RSV, and influenza. Serology 
was negative for arboviruses, EBV, and mycoplasma. CSF was negative for HSV and 
enterovirus by polymerase chain reaction.
A search of VAERS revealed reports of febrile seizures following routine administration of 
the combination vaccine (DTaP-IPV-HepB) and pneumococcal conjugate vaccine, and 
reports in the literature also supported this association [26]. When this case was reviewed in 
January of 2006, the CCCR working group assessed this case as probably causally related to 
the vaccines due the following details: the vaccine was administered before the adverse 
event, the temporal relationship was compatible with a known biological mechanism, there 
was some evidence in the literature for a causal relationship, and other known causes were 
excluded or unlikely. The working group suggested (1) the use of prophylactic antipyretics 
following future vaccinations given the severity of her febrile reaction and evidence that 
prophylactic antipyretics may decrease febrile reactions[27], even though this may not 
reduce the risk of recurrent febrile seizure, and (2) administering the next scheduled 
vaccines separately to more clearly identify the causal vaccine if a similar event were to 
occur again [28]. The group also recommended that the provider offer education regarding 
febrile seizures and how this type of seizure may result from multiple causes other than 
vaccines.
Subsequent to the CCCR discussion, a large study reported no association between acellular 
pertussis vaccine receipt and an increased risk of seizure, even when administered 
concurrently with other vaccines. Thus, if this case were reviewed by our experts at a later 
Williams et al. Page 4
Vaccine. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
date, the causal assessment may have been different. This case demonstrates the difficulty of 
causality assessment and the importance of expert evaluations of AEFI who can apply the 
most current evidence of association for these reviews.
Case 2
A 4 year old male with a previous history of mild allergic rhinitis developed a very large 
local reaction of the left upper arm within 6 hours following the fifth DTaP vaccine and first 
hepatitis A (Hep A) vaccine in that arm, and the second measles, mumps and rubella vaccine 
(MMR) in his right arm. The next day, a physician diagnosed left arm cellulitis and treated 
with cefprozil. The following day, another provider reevaluated him and discontinued the 
antibiotics. The localized swelling reaction lasted approximately 5 days, and thereafter the 
child began experiencing intermittent painful wheal and flare eruptions in the same area of 
the left arm. At his next scheduled vaccine visit, the provider elected to give boosters of Hep 
A and IPV in the right arm only. Within 6 hours, he again developed a large local reaction in 
the same area of the left arm, despite having not received any vaccines there. This reaction 
was larger and more painful than the initial one and lasted 1-2 days. Afterwards, he 
continued to have wheal and flare eruptions in the left arm 1-2 times per month, usually 
when he was overheated or exposed to the sun. At the time of the CCCR consult, the patient 
was 12 years of age and had received varicella vaccine without incident, but his parents were 
hesitant to agree to the tetanus, diphtheria, and acellular pertussis (Tdap) booster and the 
meningococcal conjugate vaccine. Family history revealed that the patient's sister had 
experienced very similar reactions following vaccines, including intermittent painful 
eruptions at the site of initial large local reactions.
The provider had diagnosed this condition as recall urticaria. However, during the CCCR 
evaluation, a pediatric allergist/immunologist suggested that the reaction was more 
consistent with a fixed-drug reaction to alum, a common adjuvant used in the vaccines given 
prior to the initial reactions in both siblings[29]. The working group recommended 
intradermal testing with aluminum and evaluation of the child's antibody levels to the target 
diseases to determine if additional doses were needed. Intradermal testing with 
meningococcal vaccine and Tdap and use of topical steroids in the event of a recurrence was 
also recommended. Finally the group reassured the primary care physician that a severe, 
immediate anaphylactic type reaction was unlikely with further vaccination. Although fixed-
drug reactions to substances other than vaccines were reported in the literature [30], there 
were no reports of a fixed-drug reaction or recall urticaria related to alum or the specific 
vaccines administered. Therefore, in accordance with the criteria for causality used by the 
working group, this AEFI was assessed as most likely a fixed drug reaction that was possibly 
causally related to the vaccination because the vaccine was given prior to the event, the 
medical literature did not establish or refute a causal relationship, and other known causes of 
the event that were more likely were excluded. This case demonstrates the value of including 
subject matter experts in the review of complex AEFI.
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Results
Demographics and Characteristics of Case Population
From April 14, 2004 until December 31, 2009, 76 AEFI were reviewed on 68 CCCR calls. 
One patient experienced two separate and different adverse events after two different 
immunizations and both were evaluated separately. The age of patients ranged from 2 days 
to 85 years with 52.6% female. (Table 2)
A past medical history was available in 71 of 76 cases (93.4%). (Table 2) Of these 71, 27 
were previously healthy and the other 44 had current or chronic medical conditions, or were 
receiving relevant treatments for chronic illnesses. Geographically, 12 states were 
represented with 30 cases from Tennessee, 19 from California, 8 from New York, 4 from 
Maryland, 3 from Colorado, 2 each from Pennsylvania, Florida, and Georgia, and one each 
from Michigan, Ohio, Arkansas, South Carolina, Utah and Texas. There was one case where 
the geographical location of the patient was unknown.
Description of Case Data Collected
The primary organ system involved with the AEFI was determined. The neurological system 
was the most commonly affected organ system among these cases and represented a broad 
range of diagnoses, including transverse myelitis, meningitis, Bell's Palsy, and seizures. 
(Table 3) Other organ systems included 11 multisystem, 11 dermatologic, 6 hematologic, 5 
musculoskeletal, 3 cardiac, 2 gastrointestinal, 2 psychiatric and one each endocrine, 
lymphatic, and vascular. The reviewed AEFI were associated with all routinely 
recommended vaccines. (Table 3) In 50% of cases reviewed, multiple vaccines were given 
simultaneously during the vaccine visit prior to the event.
For each AEFI, the working group considered whether another cause for the event could be 
identified (e.g., concurrent viral illness, current medication with similar adverse event 
profile). In 41 cases (54.0%) another known or likely cause of the adverse event was 
identified, in 25 (32.9%) there was no other explanation for the event, and in 10 (13.2%) 
there was insufficient information to assess other possible causes. VAERS searches 
identified similar AEFI associated with the specific vaccine(s) in 63 (82.9%) cases and the 
PubMed literature search resulted in similar AEFI reports with the same vaccine in 38 
(50.0%) cases. Two cases did not have sufficient information to allow a specific PubMed 
search.
Causality Assessment and Recommendations
According to the modified WHO criteria (Table 1), causality was classified as definite in 3 
cases (3.9%), probable in 12 cases (15.8%), possible in 16 cases (21.1%), unlikely in 18 
cases (23.7%), and unrelated in 10 cases (13.2%). In 17 cases (22.4%), the working group 
had insufficient information to assess causality. Among 15 cases with definite or probable 
causality assessments, 2 were related to yellow fever vaccine (viscerotropic disease and 
multi-system failure) [31-32], 2 were localized abscesses [33], 2 involved systemic febrile 
and localized swelling reactions [33], and 2 involved infections with a vaccine strain 
(disseminated varicella and chronic diarrhea due to rotavirus) [34-35]. (Table 4) A case 
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involving seizures, cerebral edema, and hepatic abnormalities after MMR and hepatitis B-
Hib combination vaccine was judged to be probably related to a prolonged febrile seizure 
[36]. Other cases assessed as probable included neuritis following DTaP and Hep B vaccines 
[37-38], febrile reaction and myalgia associated with DTaP [39], complex regional pain 
syndrome following Td vaccine [40], and cerebellar ataxia associated with varicella vaccine 
[41].
Among the 36 neurologic cases, eight met our criteria for possibly vaccine-related, with an 
appropriate temporal relationship, the literature did not confirm or refute the causal 
relationship, and more likely known causes were excluded. (Table 3) For example, one case 
of transverse myelitis occurred 2 weeks after receipt of DTaP, seven-valent pneumococcal 
(PCV-7), and Hib vaccines. However, the child also had a prior infection and there was not 
enough evidence to determine if this infection would be considered a “more likely” cause 
[42]. Another case of prolonged inconsolable crying following the administration of DTaP 
was assessed as possibly causally related to vaccine since there is evidence of a causal 
association between prolonged crying and the pertussis component of the previously 
recommended DTP vaccine [43], but less evidence of such an association with DTaP [44].
Survey response
Follow up surveys were returned by 30 of 52 (57.7%) providers. Of these, 28 (93.3%) 
described the service as helpful. Two providers were dissatisfied; one cited too long of a 
waiting period for recommendations following consultation and the other did not feel they 
received enough information regarding risk for revaccination. We also asked whether case 
patients experienced further adverse events after future vaccinations or whether they refused 
them. Three respondents reported that the subjects planned to forego further immunizations 
because of the adverse event. Eleven case-patients received additional immunizations 
without problems, but the specific vaccines administered were not necessarily those 
associated with the original event. Ten survey responders were uncertain as to whether the 
patients received additional vaccines and two responded that there was no need for 
additional vaccines.
Discussion
The primary goal of the CCCR was to create an accessible team of experts to examine AEFI 
and provide recommendations to the consulting party regarding future immunization risks 
and the likelihood of causal association between the vaccine and the AEFI. Although we 
were presented with cases affecting all organ systems, many of the cases were related to the 
neurological system. (Table 3) The large number of neurological cases likely resulted from 
selection and reporting bias due to the severity of these cases and previously reported 
relationships between vaccination and specific neurologic AEFI in the literature [11, 13] 
[45]. Also, reports of hypersensitivity and Guillian-Barré syndrome were evaluated 
separately by two other specific CISA working groups
We determined that another cause rather than the vaccination was “possible” in half of the 
cases referred to the CCCR. However, there was often not enough information to fully 
evaluate other causes. In half of cases reviewed, multiple vaccines were administered 
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simultaneously, making it difficult to determine which vaccine might have been associated 
with the AEFI. Although others have reported that the administration of multiple vaccines 
simultaneously or in fixed combinations has not been shown to increase AEFI over single 
administrations, it complicated the evaluation [45-46].
The predominance of children over adults in the CCCR likely reflects the larger number of 
vaccines children receive in comparison to adults. Our patient population was equally 
distributed by gender. The majority of AEFI cases lived in states with CISA sites, namely 
Tennessee, California, New York, and Maryland, suggesting greater awareness of the service 
in these areas.
Having an expert panel with subspecialty representation, particularly from neurology and 
allergy/immunology, to distinguish between an underlying disease process and the potential 
causal association with a vaccine is a beneficial component of the CCCR service [47]. For 
example, a provider may believe that a given vaccination was likely responsible for a 
temporally related exacerbation of multiple sclerosis (MS), but input from neurologic 
consultants could reassure the practitioner that MS exacerbations are common and that 
multiple studies have not supported their increased risk after vaccination [48]. Also, panel 
experts can clarify the most likely diagnosis, such as the fixed-drug reaction to aluminum in 
Case 2 and provide appropriate recommendations regarding future immunization options.
One limitation of the CCCR is that only a limited number of AEFI cases could be reviewed 
during monthly calls. During the recent H1N1 pandemic, the CCCR effectively responded to 
an increased demand by scheduling weekly CCCR calls to review AEFI following the H1N1 
vaccine. Another potential limitation was that the working group accepted the case 
diagnoses reported by the providers in most instances. Although specific case definitions for 
AEFI are available through the Brighton Collaboration [49], most CCCR cases reviewed 
were not diagnoses with established Brighton definitions. The use of Brighton definitions in 
other CISA projects has proven helpful and should be considered for future CCCR cases for 
which a Brighton case definition exists. Also, more Brighton definitions for other common 
AEFI would be helpful. Additional limitations result from the retrospective nature of this 
review, including limited information of past medical and family history, variability in 
specific case data available, and the inability to reach several original consulting providers in 
preparation for this review. The range of cases presented was also impacted by the limited 
geographical location of the CISA sites and the limited national awareness of the CCCR 
service.
The most challenging aspect of this endeavor was and continues to be causality assessment. 
As clearly demonstrated in Case 1, new studies evaluating vaccine associated adverse events 
are continually published. Thus, our experts are charged with knowing the most recent data 
and applying it to their understanding of vaccine safety at the time of the case review. 
Overall, a significant number of cases did not have sufficient information to assign causality. 
Such uncertainty could be reduced, however, by more complete case histories and improved 
access to patient information after the initial referral.
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Through our use of the modified WHO criteria for causality assessment, we identified areas 
where application of the criteria was problematic. The definitions for different levels of 
causality are often unclear and inconsistent from level to level (e.g. “temporal relationship” 
versus “timing of onset”). Also, the criteria for causality levels concerning “other known 
causes” are difficult to interpret and apply, and the criteria for evidential support lack strict 
definitions for each causality determination (e.g., the difference between “substantial” and 
“some” evidence). In spite of these limitations, knowledgeable experts in vaccine safety who 
were participants in the CCCR were able to assess causality based on these criteria. CISA is 
currently developing a more comprehensive algorithmic approach for evaluating individual 
cases of AEFI which will address these identified limitations.
Other countries have developed alternative methods for systematic reviews of AEFI. The 
“Green Channel” in one region of Italy provides a counseling service to a population of 4.5 
million. This service allows local health departments to evaluate patients with a history of 
AEFI prior to vaccination, provides a real time consultation service regarding AEFIs with 
contact capabilities by telephone, fax, or e-mail, and encompasses a surveillance system 
similar to what is available in the US through VAERS [50-51]. Another consultation service 
for providers is available in Switzerland (population approximately 7.7 million). This system 
is e-mail based, with an “on-call” expert in vaccine safety available to respond to questions 
and additional access to the entire vaccine safety expert group for comment [52]. Both 
examples provide services for much smaller populations than the entire U.S. and a similar 
approach in the U.S. would prove challenging. The CCCR is only one component of an 
extensive vaccine safety monitoring system which serves the unique role of addressing 
individual cases of AEFIs, and as evidenced by our review during the H1N1 pandemic, this 
service could be enhanced to accommodate more cases if needed.
Another potential approach to the evaluation of AEFI would be to establish specific 
protocols for practitioners to follow such as the recently published CISA guidelines for 
assessment of patients with possible hypersensitivity reactions [53]. For example, obtaining 
viral titers and cultures and Lyme disease serology could establish that a recent infection, 
rather than a recently administered vaccine, was the cause of Bell's palsy. CISA maintains a 
sample repository and timely collection of specimens may aid in establishing causality, as 
well as providing biologic samples for future studies designed to further address these 
questions. Such protocols could include detailed instructions on obtaining specimens, 
conducting thorough physical examinations, and complete medical history forms, which 
could then be submitted to the CCCR team for a more comprehensive evaluation. The 
previously established CDC guidelines to evaluate possible adverse events following 
smallpox immunization also serves as a model for similar protocols [54].
Given the positive responses from our survey, it does appear that primary care physicians 
find the CCCR services beneficial. We believe that the CCCR works well in the academic 
environment, where the review team can call upon subspecialty experts relatively quickly. 
However, many providers are not aware of this service and as the CCCR becomes more 
recognized, it is likely that the demand would increase. Although there are no charges to the 
providers for this service, 3 to 4 hours of coordinator and investigator time were spent in 
preparing and scheduling the cases, 1 to 2 hours were spent in discussing the cases, and 1 to 
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2 hours were spent in providing follow up letters to outline the results and recommendations. 
This activity was supported through CISA funding. We believe that addressing public 
concerns about immunizations in an easily accessible format through a systematic process 
facilitates trust in immunization recommendations, adds to the vaccine safety monitoring 
infrastructure, and provides a forum where complex adverse events following vaccination 
can be thoroughly evaluated [55].
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Abbreviations
DTaP diphtheria and tetanus toxoids and acellular pertussis
HepA hepatitis A
HepB hepatitis B
Hib Haemophilus influenzae type b
HPV human papillomavirus
IPV inactivated poliovirus
LAIV live, attenuated influenza vaccine
MCV4 quadrivalent meningococcal conjugate vaccine
MMR measles, mumps, and rubella
MMRV measles, mumps, rubella, and varicella
MPSV4 quadrivalent meningococcal polysaccharide vaccine
PCV pneumococcal conjugate vaccine
PPSV pneumococcal polysaccharide vaccine
PRP-OMB polyribosylribitol phosphate-meningococcal outer membrane protein 
conjugate
Td tetanus and diphtheria toxoids
TIV trivalent inactivated influenza vaccine
Tdap tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis
Var varicella vaccine
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Table 1
WHO causality assessment criteriaa compared with CISA investigator modified criteriab used in this report
CISA Modified Criteria Original WHO criteria
Definite The report documents that the vaccine was given before the onset of 
the signs and symptoms and that the timing of onset was consistent 
with a known mechanism or published literature; there is substantial 
existing evidence in the medical literature establishing a causal 
relationship between vaccine(s) and the event, and other known 
causes of the event had been excluded.
Very 
Likely / 
Certain
Clinical event with plausible time 
relationship to vaccine administration, and 
which cannot be explained by concurrent 
disease or other drugs or chemicals
Probable The report documents that the vaccine was given before the onset of 
symptoms and that the temporal relationship was consistent with a 
biologic mechanism or published literature; there is some evidence 
in the medical literature for a causal relationship between vaccine(s) 
and the event, and other known causes of the event had been 
excluded or were unlikely.
Probable Clinical event with a reasonable time 
relationship to vaccine administration, and 
is unlikely to be attributed to concurrent 
disease or other drugs or chemicals
Possible The report documents that the vaccine was given before the onset of 
symptoms; the medical literature does not establish or refute a 
causal relationship between vaccine(s) and the event, and known 
causes that are more likely associated with event had been 
excluded*.
Possible Clinical event with a reasonable time 
relationship to vaccine administration, but 
which could also be explained by 
concurrent disease or other drugs or 
chemicals
Unlikely The report documents that the vaccine was given before the onset of 
symptoms; the medical literature does not establish or refute a 
causal relationship between vaccine(s) and the event, and there were 
other known causes of the clinical event that were more likely 
and/or had not been excluded*.
Unlikely Clinical event whose time relationship to 
vaccine administration makes a causal 
connection improbable, but which could 
plausibly be explained by underlying 
disease or other drugs or chemicals
Unrelated The onset of the event was prior to vaccine administration; or there 
is substantial evidence in the medical literature that the vaccine does 
not cause the event; or there was a co-existing disease/condition, 
drug, or vaccine that caused the event; or the temporal relationship 
between vaccination and the event was not consistent with the 
biological onset of clinical event.
Unrelated Clinical event with an incompatible time 
relationship to vaccine administration, and 
which could be explained by underlying 
disease or other drugs or chemicals.
aCollet JP, MacDonald N, Cashman N, et al. Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert 
advisory committee. Advisory Committee on Causality Assessment. Bull World Health Organ. 2000;78(2):178-185.
b
Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM. Serious adverse events rarely reported after trivalent inactivated 
influenza vaccine (TIV) in children 6-23 months of age. Vaccine 2009 Jul 9;27(32):4278-83.
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Table 2
Demographics and Characteristics of 76 Cases Reviewed, CISA Clinical Case Review, 2004-2009
Age
    Range (IQR) 2 days – 85 years (1.3 - 26)
    < 18 yr, n (%) 49 (64.5%)
    > = 18 yr, n (%) 27 (35.5%)
Female 40 (52.6%)
Current or chronic medical conditiona
    Yes 44 (57.9%)
    No 27 (35.5%)
Underlying known medical conditionsb
    Atopy (asthma +/− eczema +/− allergic rhinitis +/− food allergy) 13 (17.1%)
    Immune abnormality (SCIDc, cancer, Kawasaki disease, congenital neutropenia, pregnancy) 6 (7.9%)
    Autoimmune disorders (psoriasis, thyroid disorder, Sjogren's syndrome) 4 (5.3%)
    Previous similar reaction or event 3 (4.0%)
    Multiple medical problems 9 (11.8%)
    Known medical history that could be causal (i.e., specific medicine associated with event, acute worsening of 
previous condition)
13 (17.1%)
a
Data on past medical history available from 71 (93.4%) cases
b
categories are not mutually exclusive
cSevere Combined Immunodefiency
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Table 3
Characteristics of 35 Cases with Neurological Events Reported After Immunization, CCCR 2004-2009.
Age (yrs) Diagnosisa Time interval 
from 
vaccination 
to 
symptoms 
(days)
Vaccine(s) Past medical history Causality
0.5 Brachial neuritis 7 DTaP Healthy Probable
0.8 Status epilepticus 0.75 HepB, IPV, DTaP 
(given in fixed 
combination), 
PCV-7
Healthy Probable
1.5 Cerebellar ataxia 9 DTaP, Hib, HepB, 
MMR, Var
Healthy Probable
16 Periodic myalgia 0.5 DTaP, HepB, IPV, 
Var
Asthma Probable
29 Neuritis 29 HepB Unknown Probable
0.1 Inconsolable crying <1 HepB, IPV, DTaP, 
PCV-7, Hib
Healthy Possible
0.3 Bulging fontanelle, fussy 0.3 Hib, DTaP, HepB, 
IPV, PCV-7, 
Rotavirus
Healthy Possible
0.6 Transverse myelitis 14 DTaP, PCV-7, Hib Healthy Possible
12 CIDPc <21 MCV4, HepA TdaP Healthy Possible
13 Transverse Myelitis 18 Var, HepA Seasonal allergies, asthma, 
eczema
Possible
39 Meningitis/ Meningoencephalitis 2 LAIV Concurrent URI Possible
54 Facial diplegia 7 TIV Elevated cholesterol, HTN, 
shrimp allergy
Possible
74 Acute polyneuropathy 1 PPSV, TIV Chronic proctitis Possible
9 Generalized seizure 2 LAIV Seasonal allergies Unlikely
14 Meningitis 7 MCV4 Concussion Unlikely
14 Primary muscular atrophy vs autoimmune 
polyneuropathy
90 HPV Delayed early gross motor Unlikely
15 Intracerebral vessel inflammation 10 HepA, MCV4 Exercise induced asthma, h/o 
trauma to orbit
Unlikely
18 Pseudotumor cerebri exacerbation 30 HPV Pseudotumor cerebri, scoliosis Unlikely
21 Amyotrophic Lateral Sclerosis vs. 
Pharyngeal-Cervical Brachial variant GBS
270 HPV Developmental delay motor, 
hypothyroidism, h/o purpura 
fulminans with varicella
Unlikely
36 Temporal lobe epilepsy 11 MMR Healthy Unlikely
57 GBS 44 HepA, HepB, Td, 
TYP, YF
Healthy Unlikely
61 Exacerbation of idiopathic inflammatory 
disease of CNS
10 TIV Unknown Unlikely
64 Encephalitis vs ADEMc 3 TdaP Smoker, high cholesterol Unlikely
1.2 Pallid infant syncope 6 MMR Kawasaki in future Unrelated
16 Aseptic meningitis 0.75 MCV4, TdaP, HepA “allergies” Unrelated
17 Aseptic meningitis < 30 MCV4, TdaP, HepA Healthy Unrelated
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Age (yrs) Diagnosisa Time interval 
from 
vaccination 
to 
symptoms 
(days)
Vaccine(s) Past medical history Causality
17 Mental status change 1 HPV, MCV4 Healthy Unrelated
18 Chronic fatigue syndrome 18 RBV Lyme disease, future dx of 
hashimoto's
Unrelated
0.5 ADEMb 5 DTaP, IPV, HepB (given in fixed 
combination), Hib, 
PCV-7, Rotavirus
Concurrent febrile illness Insufficient information
26 Bell's palsy Unknown HPV Healthy Insufficient information
Mid-40s Neuromuscular weakness 1 TIV Healthy Insufficient information
67 Myelopathy 35 PPV Previous lesion on MRI Insufficient Information
63 Bell's palsy 1 Td, HepA, HepB, 
YF
Unknown Insufficient information
77 Encephalitis/aseptic meningitis/vitritis/retinitis >60 YF Unknown Insufficient information
85 Bell's Palsy vs Ramsay Hunt syndrome 21 Zos MI Insufficient information
a
The CCCR accepted the diagnoses as given to us by providers and made no effort to independently verify the diagnoses.
bAcute Demyelinating Encephalomyelopathy
cChronic Inflammatory Demyelinating Polyneuropathy
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Table 4
Characteristics of 15 Cases with Causality Assessments of “Definite” or “Probable”, CISA Clinical Case 
Review, 2004-2009
Age Vaccine(s) Diagnosis Time Interval Past Medical History Causality
4 mo. Rotavirusb Rotavirus positive (confirmed vaccine 
strain) chronic diarrhea†
90 days later dxwith SCIDab Definite
1 yr. MMR, Varb, Hep B, 
PCV-7
Disseminated varicellab 23 days reactive airway disease, prolonged hospitalization 
with pneumonia, dx with 
SCIDab after this illness
Definite
22 yr. YFb, Typ, Hep A, Td Yellow Fever Viscerotropic Diseaseb 1 day Asthma Definite
16 yr. DTaPb, Hep B, IPV, Var Periodic myalgiab < 1 day Asthma Probablec
4 mo. IPV, DTaP, PCV-7, 
Hib/Hep B
Abscess,sterile 21 days None Probable
6 mo. Hep B, IPV, PCV-7 Abscess, pyogenic 7 days Eczema Probable
6 mo. DTaPb Brachial neuritisb 7 days None Probable
10 mo. Hep B, IPV, DTaPb 
(combination) and PCV-7
Febrile seizureb, status epilepticus < 1 day None Probable
1 yr. MMRVb, HepB-Hib Seizureb, cerebral edema, liver and 
endocrine instability
8 days Unknown Probable
1.5 yr DTaP, Hib, Hep B, MMR, 
Varb
Cerebellar ataxiab 9 days None Probable
29 yr. Hep Bb Neuritisb < 1 day Unknown Probable
36 yr. Tdb ComplexRegional Pain Syndromeb < 1 day Obesity Probable
67 yr. TIVb, Zos Febrile illnessb, Local reaction < 1 day Sjogren's Probable
70 yr. TIVb, Zos Febrile illnessb, local reaction < 1 day None Probable
77 yr. YFb, Tdap, TIV Multisystem organ failureb 5 days Factor V Leiden deficiency, hyperlipidemia, 
diabetes, obesity, 
hypertension
Probable
aSevere Combined Immunodeficiency
b
Denotes a documented association between the vaccine and the adverse event (see text for explanations of unfootnoted associations). [34-35, 
56-59] [33, 38-39, 41, 43, 60]
cCausality assessment for first occurrence only.
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